PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Public ClinicalTrials.gov record NCT00911170. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in patients with newly diagnosed, locally-advanced or metastatic colorectal cancer receiving first-line treatment with bevacizumab and either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI). This study will also investigate the effect of adding pegfilgrastim to bevacizumab and either FOLFOX or FOLFIRI by evaluating overall survival, progression-free survival, and overall response rate in each arm at regular intervals over a maximum of 60 months follow-up.
Study identification
- NCT ID
- NCT00911170
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 847 participants
Conditions and interventions
Conditions
Interventions
- Pegfilgrastim Drug
- Placebo Drug
- Bevacizumab Biological
- Standard Chemotherapy Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 3, 2009 (Actual)
- Primary completion
- Sep 17, 2012 (Actual)
- Completion
- Jan 2, 2015 (Actual)
- Last update posted
- Dec 29, 2017
2009 – 2015
United States locations
- U.S. sites
- 72
- U.S. states
- 30
- U.S. cities
- 69
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Muscle Shoals | Alabama | 35661 | — |
| Research Site | Jonesboro | Arkansas | 72401 | — |
| Research Site | Anaheim | California | 92801 | — |
| Research Site | Beverly Hills | California | 90211 | — |
| Research Site | Modesto | California | 95355 | — |
| Research Site | San Diego | California | 92161 | — |
| Research Site | Greenwich | Connecticut | 06830 | — |
| Research Site | Dover | Delaware | 19901 | — |
| Research Site | Gainesville | Florida | 32605 | — |
| Research Site | Loxahatchee Groves | Florida | 33470 | — |
| Research Site | Port Saint Lucie | Florida | 34952 | — |
| Research Site | Tamarac | Florida | 33321 | — |
| Research Site | Honolulu | Hawaii | 96813 | — |
| Research Site | Gurnee | Illinois | 60031 | — |
| Research Site | Maywood | Illinois | 60153 | — |
| Research Site | Quincy | Illinois | 62301 | — |
| Research Site | Rockford | Illinois | 61108 | — |
| Research Site | New Albany | Indiana | 47150 | — |
| Research Site | South Bend | Indiana | 46617 | — |
| Research Site | Council Bluffs | Iowa | 51503 | — |
| Research Site | Sioux City | Iowa | 51101 | — |
| Research Site | Waterloo | Iowa | 50701 | — |
| Research Site | Waterloo | Iowa | 50702 | — |
| Research Site | Hutchinson | Kansas | 67502 | — |
| Research Site | Hazard | Kentucky | 41701 | — |
| Research Site | Lexington | Kentucky | 40503 | — |
| Research Site | Paducah | Kentucky | 42001 | — |
| Research Site | Shreveport | Louisiana | 71103 | — |
| Research Site | Bethesda | Maryland | 20817 | — |
| Research Site | Cumberland | Maryland | 21502 | — |
| Research Site | Randallstown | Maryland | 21133 | — |
| Research Site | Towson | Maryland | 21204 | — |
| Research Site | Boston | Massachusetts | 02130 | — |
| Research Site | Boston | Massachusetts | 02135 | — |
| Research Site | Jefferson City | Missouri | 65109 | — |
| Research Site | Kansas City | Missouri | 64118 | — |
| Research Site | Springfield | Missouri | 65807 | — |
| Research Site | St Louis | Missouri | 63136 | — |
| Research Site | Billings | Montana | 59101 | — |
| Research Site | Grand Island | Nebraska | 68803 | — |
| Research Site | Kearney | Nebraska | 68845 | — |
| Research Site | Omaha | Nebraska | 68131 | — |
| Research Site | Portsmouth | New Hampshire | 03801 | — |
| Research Site | Little Silver | New Jersey | 07739 | — |
| Research Site | Somerville | New Jersey | 08876 | — |
| Research Site | Albuquerque | New Mexico | 87131 | — |
| Research Site | Lake Success | New York | 11042 | — |
| Research Site | Nyack | New York | 10960 | — |
| Research Site | Asheville | North Carolina | 28801 | — |
| Research Site | Hickory | North Carolina | 28602 | — |
| Research Site | High Point | North Carolina | 27262 | — |
| Research Site | Winston-Salem | North Carolina | 27103 | — |
| Research Site | Canton | Ohio | 44708 | — |
| Research Site | Cincinnati | Ohio | 45219 | — |
| Research Site | Massillon | Ohio | 44646 | — |
| Research Site | Middletown | Ohio | 45042 | — |
| Research Site | Lancaster | Pennsylvania | 17605 | — |
| Research Site | Langhorne | Pennsylvania | 19047 | — |
| Research Site | Reading | Pennsylvania | 19605 | — |
| Research Site | Upland | Pennsylvania | 19013 | — |
| Research Site | West Reading | Pennsylvania | 19611 | — |
| Research Site | Willow Grove | Pennsylvania | 19090 | — |
| Research Site | Hilton Head Island | South Carolina | 29926 | — |
| Research Site | Myrtle Beach | South Carolina | 29572 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Bryan | Texas | 77802 | — |
| Research Site | Corpus Christi | Texas | 78405 | — |
| Research Site | Corpus Christi | Texas | 78412 | — |
| Research Site | Abingdon | Virginia | 24211 | — |
| Research Site | Lynchburg | Virginia | 24501 | — |
| Research Site | Kennewick | Washington | 99336 | — |
| Research Site | Spokane | Washington | 99220 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00911170, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 29, 2017 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00911170 live on ClinicalTrials.gov.